Trial Profile
A multi-centre, retrospective study of Brentuximab-Vedotin in patients with relapsed refractory Hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 03 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology